Диагностика и лечение больных острым инфарктом миокарда с подъемом ST электрокардиограммы. Клинические рекомендации. Неотложная кардиология, 2014, 1: 42-62.
Мареев В.Ю., Скворцов А.А. Блокада эффектов альдостерона у больных сердечной недостаточностью: современный взгляд на проблему - эплеренон (часть II). Сердечная Недостаточность, 2011, 12 (4 (66)): 222-227,
Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная Недостаточность, 2013, 14 (7 (81)).
Терещенко С.Н., Жиров И.В. Хроническая сердечная недостаточность. В кн.: Руководство по кардиологии. Под ред. Е.И. Чазова. М.: Практика, 2014. Т. 4. С. 192-291.
Терещенко С.Н., Жиров И.В., Осмоловская Ю.Ф. Антагонисты минералокортикоидных рецепторов в лечении больных с сердечной недостаточностью после инфаркта миокарда с хронической сердечной недостаточностью. Терапевтический архив, 2013, 85 (12): 137-144.
Федеральные клинические рекомендации по диагностике и лечению хронической и острой сердечной недостаточности. Евразийский кардиологический журнал, 2014, 2: 4-38.
ACCF/AHA Guideline for the management of heart failure. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2013, 128: e240-e327.
ACCF/AHA Guideline for the management of ST-elevation myocardial infarction. A report of the American College of Cardiology Foundation/American Heart Association. Circulation, 2013, 127: e362-e425.
Arriza JL, Weinberger C, Cerelli G et al. Cloning of human mineralocorticoid receptor comple-mentory DNA: structural and functional kinship with the glucocorticoid receptor. Science, 1987, 237 (4812): 268-275.
Arriza JL, Weinberger C, Cerelli G et al. Cloning of human mineralocorticoid receptor comple-mentory DNA: structural and functional kinship with the glucocorticoid receptor. Science, 1987, 237 (4812): 268-275.
Cook CS, Berry LM, Kim DH et al. Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5. Drug Metab Dispos., 2002, 30 (12): 1344-1351.
Degasparo M, Joss U, Ramjoue, et al. Three new epoxy-spironolactone derivates: characterization in vivo and in vitro. J Pharmacol Exp Ther, 1987, 240: 650-6.
Delyani J, Myles K, Funder J, et al. Eplerenone (SC 66110), a highly selective aldosteron antagonist. Am J Hypertens, 1998, 11: 94A.
Desai AS, Lewis EF, Li R, et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J., 2011, 162(6): 966-972. e910.
Deswal A, Richardson P Bozkurt B, Mann DL. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail., 2011, 17(8): 634-642.
Edelmann FWR, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The Aldo-DHF randomized controlled trial. JAMA, 2013, 309(8): 781-791.
Edwards NC, Ferro CJ, Kirkwood H, et al. Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. Am J Cardiol., 2010, 106(10): 1505-1511.
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Heart Journal, 2012, 33: 1787-1847.
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2011, 32: 2999-3054.
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2012, 33: 2569-2619.
Montalescot G, Pitt B, Lopez de Sa E et al. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study. European Heart Journal, 2014; DOI: 10.1093/eurheartj/ehu164..
DOI: 10.1093/eurheartj/ehu164
J. Guichard, Donald Clark II, D. A Calhoun et al. Aldosterone receptor antagonists: current perspectives and therapies. Vascular Health and Risk Management, 2013, 9: 321-331.
Lee AF, MacFadyen RJ, Struthers AD. Neuro-hormonal reactivationin heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur J Heart Fail., 1999, 1(4): 401-406.
Mak GJ, Ledwidge MT, Watson CJ, et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol., 2009, 54(18): 1674-1682.
McMachon E. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Current Opinion in Pharmacology, 2001, 1: 190-6.
Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation, 2004, 110(5): 558-565.
Muller J. Regulation of aldosterone biosynthesis: physiological and clinical aspects. Monographs on Endocrinology. 2nd ed. N.Y.: Springer-Verlag, 1988.
Muller J. Spironolactone in the management of congestive heart failure: a rewiew. Clin Ther., 1986, 9(1): 63-76.
Pitt B, Remme W, Zannad F, et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med, 2003, 348: 1309-21
Pitt B, Roniker B. Eplerenone, a novel selective aldosteron receptor antagonist (SARA): dose -finding study in patients with heart failure. J Am Coll Cardiol., 1999, 33: 188A-9A.
Pitt B, Zannand F, Remme W, et al. The effect of spircnclactone on morbidity and mortality in patients with severe heart failure. N Engl J Med, 1999, 341: 709-17.
Sadee W, Dagcioglu M, Schroder R. Pharmaco-kinetics of spironolactone, canrenone and can-renoate-K in humans. J Pharmacol Exp Ther., 1973, 185(3): 686-695.
Sato A, Saruta T. Aldosterone escape during angi-otensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res., 2001, 29 (1): 13-21.
Smith AG. Spironolactone in the long-term management of patients with congestive heart failure. Curr Med Res Opin., 1980, 7(2): 131-136.
Swedberg K, Zannad F, McMurray JJ et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-Hf (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol., 2012, May 1, 59(18): 1598-603.
Urata H, Healy BH, Stewart R et al. Angiotensin II forming pathways in normal and failing human hearts. Circ Res., 1990, 66(4): 883-390.
Weber KT, Villarreal D. Aldosterone, and antial-dosterone therapy in congestive heart failure. Am J Cardiol, 1993, 71 (Suppl. A): 3A-11A.
Yasky J, Ledesma GA, Tutera A, Collia LF. A fixed-dose combination of furosemide and spironolac-tone in digitalized congestive heart failure patients. Pharmatherapeutica, 1986, 4(8): 480-485.
Zannad F, McMurray JJV, Drexler H et al. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail., 2010,12 (6):617-622.
Zannad F., McMurray JJV, Krum H. et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med, 2011, 364: 11-21.